Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4Gastrointestinal 4

Conditions

Gastrointestinal Stromal Tumors 4

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × ripretinib × Clear all
NCT04633122 2026-04-03

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Zai Lab (Hong Kong), Ltd.

Phase 2 Completed
108 enrolled 11 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03673501 2026-02-05

INTRIGUE

Deciphera Pharmaceuticals, LLC

Phase 3 Active not recruiting
453 enrolled 20 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04282980 2025-03-03

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

Zai Lab (Hong Kong), Ltd.

Phase 2 Completed
39 enrolled 13 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03353753 2022-11-21

INVICTUS

Deciphera Pharmaceuticals, LLC

Phase 3 Completed
129 enrolled 19 charts 1 FDA
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡